Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children’s Oncology Group study ANBL0531

Barr EK, Naranjo A, Twist CJ, Tenney SC, Schmidt ML, London WB, Gastier-Foster J, Adkins ES, Mattei P, Handler MH, Matthay KK, Park JR, Maris JM, Desai AV, Cohn SL. Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children’s Oncology Group study ANBL0531. Pediatr Blood Cancer. 2024 Aug;71(8):e31089. doi: 10.1002/pbc.31089. Epub 2024 May 31. PubMed PMID: 38822537; PubMed Central PMCID: PMC11318088.

We previously reported excellent 3-year overall survival (OS) for patients with newly diagnosed intermediate-risk neuroblastoma treated with a biology- and response-based algorithm on the Children’s Oncology Group study ANBL0531. We now present the long-term follow-up results.